Can NK cells be a therapeutic target in human cancer?
Our current knowledge of NK-cell recognition and effector function suggests that it will be possible to design various new NK-cell-based immunotherapies against human cancer. The application of NK cells is already showing promise using HLA-mismatched haematopoietic stem cell transplantation for treatment of haematological malignancies. A better understanding of NK-cell heterogeneity and function will only broaden the applications for human cancer. Here we review the key developments that will propel this field.
Chan
Christopher J
CJ
Peter MacCallum Cancer Centre, East Melbourne, Australia.
Andrews
Daniel M
DM
Smyth
Mark J
MJ
D000818:Animals; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007157:Immunologic Surveillance; D016219:Immunotherapy, Adoptive; D007694:Killer Cells, Natural / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D014182:Transplantation, Autologous